Stock Screener App

Frei -

Installieren

2.85

0.75% -0.00

Indaptus Therapeutics Inc (INDP)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten

Indaptus Therapeutics (INDP) News Flow - Moomoo

Indaptus Therapeutics Company Profile & Introduction - Moomoo

Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia

Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan

Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan

Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan

Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa

Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused - Stock Titan

Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView

INDAPTUS THERAPEUTICSTO ISSUE 20 MLN SHARES AT $0.6 PER SHARESEC FILING - Moomoo

Indaptus TherapeuticsTo Issue 20 Million Shares At $0.6 Per ShareSEC Filing - TradingView

Indaptus Therapeutics Announces Private Placement of Common Stock - TipRanks

Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement - Stock Titan

Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share - TradingView

Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Form PRE 14A Sunshine Biopharma Inc For: 22 June By Investing.com - Investing.com Australia

Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan - Stock Titan

Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey

Indaptus Therapeutics Inc (INDP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis - TradingKey

Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Top Cue Biopharma (CUE) Competitors 2026 - MarketBeat

Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders - Caledonian Record

Indaptus Therapeutics, Inc. announced that it expects to receive $12 million in funding - marketscreener.com

INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com

12 Health Care Stocks Moving In Thursday's Intraday SessionAdial Pharmaceuticals (NASDAQ:ADIL), Aditxt - Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com

Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart

Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks

Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView

Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo

Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative

INDPIndaptus Therapeutics Inc Stock Price and Quote - Finviz

INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com

Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli

Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser

INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com

Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate

Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser

Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser

Earnings Scheduled For May 15, 2026 - Sahm

Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart

Indaptus Therapeutics Reports Q1 2026 Financial Results, Management Changes, and Strategic Review Amid Cash Constraints - Minichart

Indaptus Therapeutics reassesses decoy platform as cash dwindles - grafa.com

Indaptus Therapeutics Q1 Financial Analysis - Intellectia AI

Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

INSM

$113.49

1.16%

ROIV

$35.27

0.23%

RPRX

$57.95

1.95%

ONC

$308.33

0.48%

MRNA

$82.23

0.32%

RVMD

$190.47

0.31%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters